US stock insider trading | Glaukos disclosed three insider transactions on March 17

K-LinePoet · 2026-04-03T09:48:21+00:00

On March 17, 2026, Glaukos disclosed insider trading activity, including Board Member Burns Thomas William selling 5,212 shares on March 13. The company focuses on ophthalmic pharmaceuticals and medical technologies, dedicated to developing new therapies for diseases such as glaucoma.

K-LinePoet

2026-04-03 09:48:21

Abstract generation in progress

On March 17, 2026, Glaukos (GKOS) disclosed three transactions involving company insiders.

Director Burns Thomas William sold 5,212 shares on March 13, 2026.

【Recent Insider Trading】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Value/USD
March 17, 2026	Director	Burns Thomas William	March 13, 2026	Sold	5212	97.02	505.7k
March 17, 2026	Executive	Navratil Tomas	March 13, 2026	Sold	1074	97.02	104.2k
March 17, 2026	Executive	Gilliam Joseph E	March 13, 2026	Sold	2462	97.02	238.9k
March 9, 2026	Executive	Navratil Tomas	March 5, 2026	Sold	361	112.10	40.5k
March 9, 2026	Director	Burns Thomas William	March 5, 2026	Sold	1098	112.10	123.1k
February 26, 2026	Director	Burns Thomas William	February 24, 2026	Sold	4059	119.17	483.7k
February 26, 2026	Executive	Navratil Tomas	February 24, 2026	Sold	396	119.17	47.2k
February 26, 2026	Executive	Gilliam Joseph E	February 24, 2026	Sold	1057	119.17	126k
February 23, 2026	Director	WEISNER AIMEE S	February 19, 2026	Sold	6471	118.56	767.2k
February 23, 2026	Director	WEISNER AIMEE S	February 19, 2026	Sold	5242	116.64	611.4k

【Company Profile】

Glaukos Corporation was incorporated in the State of Delaware on July 14, 1998. The company is an ophthalmic pharmaceutical and medical technology company that focuses on developing new non-drop therapies and commercializing related products for the treatment of glaucoma, corneal diseases, and retinal diseases. They first developed minimally invasive glaucoma surgery (MIGS) as an alternative to traditional glaucoma treatment approaches and released their first MIGS device in 2012. They also offer a commercially available proprietary biologically activated drug therapy for the treatment of keratoconus, a rare corneal disease. This therapy was approved by the U.S. Food and Drug Administration (FDA) in 2016. They are developing a range of platforms to support ongoing pharmaceutical and medical device innovation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes